Reviva Pharmaceuticals Raises Funds for Schizophrenia Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Source: stocktwits
- Clear Funding Purpose: Reviva Pharmaceuticals aims to utilize approximately $10 million raised from its public offering to support its Phase 3 RECOVER-2 trial for schizophrenia, expected to launch in the first half of 2026, thereby advancing the development of its drug brilaroxazine.
- Poor Stock Performance: Following the public offering priced at $1.50 per share, Reviva's stock plummeted over 40% in pre-market trading, and if this trend continues, RVPH shares could hit a record low, reflecting market pessimism regarding the company's outlook.
- Offering Details Disclosed: The financing consists of 6.67 million shares along with Series G and Series H warrants, all immediately exercisable, with Series G valid for five years and Series H expiring in twelve months, providing investors with both short-term and long-term investment options.
- Market Sentiment Shift: Despite the stock decline, retail investor sentiment on Stocktwits shifted from neutral to bullish, with some users suggesting the company may need $60 to $70 million to complete the study, while others expressed skepticism about the ability to raise necessary funds, indicating a divide in market perceptions of Reviva's future.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
